Fineline Cube

Follow:
14691 Articles
Policy / Regulatory

China’s NHSA Issues Guiding Opinions Establishing Unified Payment Management for Long‑Term Care Insurance (LTCI)

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%
Company

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Bispecific ASP2138 for First‑Line Gastric Cancer

Others

Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT‑i

FDA Approves Revolution Medicines' Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer
CompanyDrug

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

NMPA Approves Novartis' Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
CompanyDrug

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

FDA Approves J&J's IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
CompanyDrug

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

FDA Approves BeOne's Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
CompanyDrug

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

MHLW Approves Takeda's First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
CompanyDrug

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Company

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
Company

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
CompanyDeals

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China